A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

February 28, 2015

Study Completion Date

November 30, 2016

Conditions
T-cell LymphomasT-cell LeukemiaSezary SyndromeMycosis FungoidesCutaneous T-cell Lymphoma (CTCL)
Interventions
BIOLOGICAL

A-dmDT390-bisFv(UCHT1)

A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes

Trial Locations (5)

40202

James Graham Brown Cancer Center, Louisville

76508

Scott and White Hospital & Clinic, Temple

77030

University of Texas MD Anderson Cancer Center, Houston

06520

Yale University School Of Medicine Recruiting, New Haven

75390-8562

University of Texas Southwestern Medical Center, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

James Graham Brown Cancer Center

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Scott and White Hospital & Clinic

OTHER

collaborator

University of Texas Southwestern Medical Center

OTHER

collaborator

Yale University

OTHER

lead

Angimmune LLC

INDUSTRY

NCT00611208 - A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | Biotech Hunter | Biotech Hunter